Global Myasthenia Gravis Drugs Market Research Report 2019 (Includes Business Impact of COVID-19)

                                          
"The ongoing Coronavirus (COVID-19) pandemic is re-shaping everything from global economies to product categories, pricing, and stock availability to the consumer behavior. The final report is updated to address the impact of COVID-19 on the Myasthenia Gravis Drugs market.

Trusted Business Insights is tracking mining/oil and gas, transportation, employment services, travel arrangements, and the leisure and hospitality sector closely as they are likely to be the hardest-hit sectors. Utilities, local pharma, diagnostics, consumer goods and durables, agro chem and fertilizers, and telecommunications are the sectors that will be weathering the COVID-19 storm and most likely come out relatively unscathed. Interdependencies of sectors are factored in our research report on the Myasthenia Gravis Drugs market."
Acetylcholine esterase (AChE) inhibitors are considered to be the basic treatment of myasthenia gravis (MG). Edrophonium is primarily used as a diagnostic tool owing to its short half-life. Pyridostigmine is used for long-term maintenance.
The market is witnessing the rapid development of novel drugs such as monoclonal antibodies, which is one of the primary factors driving this markets growth prospects. Most drug manufacturers are increasingly focussing on the development of monoclonal antibodies, as they act specifically on target cells; thereby, leading to lower side effects. Since conventional therapies such as acetylcholinesterase inhibitor, oral steroids, and immunomodulatory agents are associated with more side effects, physicians prefer to prescribe high efficacious monoclonal antibodies.

The global Myasthenia Gravis Drugs market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Myasthenia Gravis Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Myasthenia Gravis Drugs market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
    Flamel Technologies
    Roche
    Grifols
    Pfizer
    Shire
    Novartis
    Valeant
    Alexion
    Catalyst
    CSL
    Curavac
    Cytokinetics
    Galencia
    GlaxoSmithKline
    Lupin Pharmaceuticals
    Mitsubishi Tanabe Pharma

Segment by Regions
    North America
    Europe
    China
    Japan

Segment by Type
    Anticholinesterases
    Immunosuppressants
    Intravenous Immune Globulins

Segment by Application
    Hospitals
    Clinics